Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
CNY 4.02
(-0.74%)
CNY 4.02
(-0.74%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 86.95 Million CNY | -53.17% |
| 2022 | 196.14 Million CNY | -66.62% |
| 2021 | 587.64 Million CNY | -30.49% |
| 2020 | 845.34 Million CNY | -40.12% |
| 2019 | 1.41 Billion CNY | -3.79% |
| 2018 | 1.46 Billion CNY | 82.45% |
| 2017 | 804.29 Million CNY | 191.44% |
| 2016 | 275.97 Million CNY | -16.5% |
| 2015 | 330.49 Million CNY | -5.83% |
| 2014 | 350.96 Million CNY | 20.12% |
| 2013 | 292.17 Million CNY | 1.74% |
| 2012 | 287.17 Million CNY | 135.49% |
| 2011 | 121.95 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 10.22 Million CNY | -76.34% |
| 2024 Q1 | 43.19 Million CNY | 111.22% |
| 2024 Q3 | 34.95 Million CNY | 249.49% |
| 2023 Q1 | 45.75 Million CNY | 1170.88% |
| 2023 FY | 91.86 Million CNY | -53.17% |
| 2023 Q4 | 20.44 Million CNY | 28.48% |
| 2023 Q3 | 15.91 Million CNY | 63.29% |
| 2023 Q2 | 9.74 Million CNY | -78.7% |
| 2022 Q4 | 3.6 Million CNY | -86.24% |
| 2022 Q3 | 26.16 Million CNY | -61.74% |
| 2022 Q2 | 68.38 Million CNY | -30.23% |
| 2022 Q1 | 98 Million CNY | 104.39% |
| 2022 FY | 196.14 Million CNY | -66.62% |
| 2021 Q1 | 233.26 Million CNY | 24.05% |
| 2021 Q4 | 47.94 Million CNY | -65.05% |
| 2021 Q3 | 137.18 Million CNY | -18.94% |
| 2021 Q2 | 169.24 Million CNY | -27.44% |
| 2021 FY | 587.64 Million CNY | -30.49% |
| 2020 Q3 | 253.67 Million CNY | 37.85% |
| 2020 FY | 845.34 Million CNY | -40.12% |
| 2020 Q2 | 184.02 Million CNY | -16.2% |
| 2020 Q1 | 219.6 Million CNY | -39.69% |
| 2020 Q4 | 188.03 Million CNY | -25.87% |
| 2019 Q4 | 364.13 Million CNY | 12.48% |
| 2019 Q2 | 411.65 Million CNY | 31.81% |
| 2019 Q1 | 312.31 Million CNY | -27.29% |
| 2019 Q3 | 323.73 Million CNY | -21.36% |
| 2019 FY | 1.41 Billion CNY | -3.79% |
| 2018 Q4 | 429.54 Million CNY | 31.54% |
| 2018 FY | 1.46 Billion CNY | 82.45% |
| 2018 Q3 | 326.55 Million CNY | -24.6% |
| 2018 Q2 | 433.06 Million CNY | 55.62% |
| 2018 Q1 | 278.28 Million CNY | -24.73% |
| 2017 Q1 | 78.42 Million CNY | -17.28% |
| 2017 Q2 | 153.9 Million CNY | 96.24% |
| 2017 Q3 | 202.26 Million CNY | 31.43% |
| 2017 Q4 | 369.69 Million CNY | 82.78% |
| 2017 FY | 804.29 Million CNY | 191.44% |
| 2016 Q1 | 58.2 Million CNY | -45.37% |
| 2016 FY | 275.97 Million CNY | -16.5% |
| 2016 Q2 | 58.13 Million CNY | -0.12% |
| 2016 Q3 | 64.83 Million CNY | 11.53% |
| 2016 Q4 | 94.8 Million CNY | 46.22% |
| 2015 Q4 | 106.53 Million CNY | 40.15% |
| 2015 Q3 | 76.01 Million CNY | -11.33% |
| 2015 Q2 | 85.72 Million CNY | 37.78% |
| 2015 Q1 | 62.22 Million CNY | -47.04% |
| 2015 FY | 330.49 Million CNY | -5.83% |
| 2014 Q2 | 51.79 Million CNY | -4.42% |
| 2014 FY | 350.96 Million CNY | 20.12% |
| 2014 Q4 | 117.49 Million CNY | 58.22% |
| 2014 Q1 | 54.18 Million CNY | 0.0% |
| 2014 Q3 | 74.26 Million CNY | 43.38% |
| 2013 FY | 292.17 Million CNY | 1.74% |
| 2012 FY | 287.17 Million CNY | 135.49% |
| 2011 FY | 121.95 Million CNY | 0.0% |